Complex or recurrent liver cancer
Treatment options in Shanghai

A second liver operation is possible only when enough functioning liver can be preserved. Cirrhosis, portal hypertension, bilirubin, albumin, clotting, previous ascites and general fitness all matter. Bring the first operative report: what was removed changes both surgical access and the amount of liver left. A person who tolerated a first operation years ago may face a different risk today. Ask whether cancer extent, liver reserve or another medical condition is the main limit; that answer guides the next option.

If recurrence is limited and liver reserve is sufficient, a specialist may consider another resection. For a small focus that can be reached and treated safely, ablation may spare more liver tissue. Neither method wins by default: the site, likely treatment margin, nearby bile ducts or organs, prior anatomy and expected local control must be compared for this patient. An earlier Shanghai research profile described work on repeat resection and ablation for recurrent HCC; the practical point is to ask the team why one approach fits this lesion and liver better than the other.

When tumors are multifocal, involve vessels, spread outside the liver, or when reserve is insufficient, the discussion may move to transarterial chemoembolization (TACE), radiation, systemic immunotherapy or targeted medicines. These treatments may be used alone or in a planned sequence; each has a different aim and effect on liver function. The 2026 Chinese primary liver cancer guideline emphasizes individualized, multidisciplinary treatment. Ask three practical questions: is there still a window for local treatment, why is this option preferred now, and how will liver function be protected? Continue prescribed treatment while your treating team reviews any change.